Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENTPD1 | P49961 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | HBB | P68871 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.52 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14928421 | 0.92 | LMNA (0.56) | ENTPD1LMNATP53HBBSMN1; SMN2 | |
| SCHEMBL15248806 | 0.92 | LMNA (0.56) | ENTPD1LMNATP53HBBSMN1; SMN2 | |
| SCHEMBL15071502 | 0.92 | LMNA (0.56) | ENTPD1LMNATP53HBBSMN1; SMN2 | |
| SCHEMBL17210941 | 0.89 | P2RY2 (0.49) | ENTPD1P2RY2P2RY6 | |
| SCHEMBL15456809 | 0.88 | LMNA (0.69) | ENTPD1LMNATP53HBBSMN1; SMN2 | |
| SCHEMBL29413068 | 0.88 | LMNA (0.69) | ENTPD1LMNATP53HBBSMN1; SMN2 | |
| SCHEMBL15245119 | 0.88 | LMNA (0.69) | ENTPD1LMNATP53HBBSMN1; SMN2 | |
| SCHEMBL29810829 | 0.87 | LMNA (0.70) | ENTPD1LMNATP53HBBSMN1; SMN2 | |
| SCHEMBL14928714 | 0.85 | LMNA (0.48) | ENTPD1LMNATP53HBBSMN1; SMN2 | |
| SCHEMBL17211428 | 0.83 | NT5E (0.57) | ENTPD1LMNATP53HBBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170252461-A1 | HETEROLOGOUS UNTRANSLATED REGIONS FOR MRNA | MODERNATX, INC. | 2017-09-07 | — | — | US | disclosed |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Modema Therapeutics, Inc. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170136132-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170056528-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNATX, INC. | 2017-03-02 | — | — | US | disclosed |
| US-20160354493-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX, INC. | 2016-12-08 | — | — | US | disclosed |
| US-20160354491-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160354492-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160354490-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160348099-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-01 | — | — | US | disclosed |
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160256573-A1 | MODIFIED NUCLEIC ACIDS, AND ACUTE CARE USES THEREOF | MODERNATX, INC. | 2016-09-08 | — | — | US | disclosed |
| US-20160022840-A1 | HETEROLOGOUS UNTRANSLATED REGIONS FOR MRNA | MODERNATX, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20160022774-A1 | DIAGNOSIS AND TREATMENT OF FIBROSIS | MODERNATX, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX, INC. | 2015-10-29 | — | — | US | disclosed |
| US-20150167017-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2015-06-18 | — | — | US | disclosed |
| US-20140378538-A1 | METHODS OF RESPONDING TO A BIOTHREAT | MODERNATX, INC. | 2014-12-25 | — | — | US | disclosed |
| US-20140371302-A1 | MODIFIED MRNAS ENCODING CELL-PENETRATING POLYPEPTIDES | MODERNATX, INC. | 2014-12-18 | — | — | US | disclosed |
| US-20140343129-A1 | MODIFIED NUCLEIC ACIDS, AND ACUTE CARE USES THEREOF | MODERNATX, INC. | 2014-11-20 | — | — | US | disclosed |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160354492-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | ENTPD1 175/4885LMNA 422/4885TP53 397/4885 |
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | ENTPD1 175/4885LMNA 422/4885TP53 397/4885 |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | ENTPD1 45/4885LMNA 585/4885TP53 836/4885 |
| US-20170056528-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | ENTPD1 45/4885LMNA 585/4885TP53 836/4885 |
| US-20160348099-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | ENTPD1 175/4885LMNA 422/4885TP53 397/4885 |
| US-20160022774-A1 | DIAGNOSIS AND TREATMENT OF FIBROSIS | MMP1, COL2A1, COL1A1 | ENTPD1 1160/4885LMNA 888/4885TP53 2691/4885 |
| US-20170136132-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | ENTPD1 251/4885LMNA 571/4885TP53 411/4885 |
| US-20160354490-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | ENTPD1 175/4885LMNA 422/4885TP53 397/4885 |
| US-20160256573-A1 | MODIFIED NUCLEIC ACIDS, AND ACUTE CARE USES THEREOF | RNMT, NSUN2, NSUN3 | ENTPD1 620/4885LMNA 420/4885TP53 2322/4885 |
| US-20160354491-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | ENTPD1 175/4885LMNA 422/4885TP53 397/4885 |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | ENTPD1 251/4885LMNA 571/4885TP53 411/4885 |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | ENTPD1 251/4885LMNA 571/4885TP53 411/4885 |
| US-20160354493-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | ENTPD1 175/4885LMNA 422/4885TP53 397/4885 |
| US-20160022840-A1 | HETEROLOGOUS UNTRANSLATED REGIONS FOR MRNA | RNGTT, NSUN3, CPSF6 | ENTPD1 2495/4885LMNA 2754/4885TP53 1486/4885 |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | ENTPD1 175/4885LMNA 422/4885TP53 397/4885 |
| US-20170252461-A1 | HETEROLOGOUS UNTRANSLATED REGIONS FOR MRNA | RNGTT, NSUN3, CPSF6 | ENTPD1 2495/4885LMNA 2754/4885TP53 1486/4885 |
| US-20140378538-A1 | METHODS OF RESPONDING TO A BIOTHREAT | POLRMT, RNMT, RNGTT | ENTPD1 152/4885LMNA 1299/4885TP53 4461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.